ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law

WHAT IS GLP-1?

GLP-1 stands for “Glucagon-like peptide-1.” Think of it as a natural hormone your body makes after you eat. It does three main things:

1. Tells your pancreas to make insulin (but only when blood sugar is high)
2. Makes you feel full so you eat less
3. Slows down food leaving your stomach

NEW FDA GUIDELINES (2024-2025)

KEY CHANGES IN LABELING

The FDA has updated guidelines for GLP-1 medications due to safety concerns with compounded versions and unapproved products:

MAJOR UPDATES:

Transition to FDA-approved products by May 22, 2025 for better
quality assurance
New “green list” established to ensure high-quality GLP-1
ingredients from verified

sources
Enhanced oversight to maintain pharmaceutical standards

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The
products offered on this website are furnished for in vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the
body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical
condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law

RESEARCH GUIDELINES:

Clinical studies focus on expanding understanding of GLP-1 effectiveness across diverse populations Ongoing research to optimize dosing protocols and minimize side effects Continued monitoring to establish long-term safety profiles

NEW APPROVALS AND LABEL UPDATES

First generic GLP-1 for weight loss approved (generic liraglutide)
priced 30% less than Saxenda Semaglutide label updated to allow use as first-line therapy for
type 2 diabetes
New guidelines for continuing GLP-1 medications before surgery released by multiple medical societies

TYPES OF GLP-1
RESEARCH CLASSIFICATIONS

Based on current research, here are the main GLP-1 categories:

1. GLP-1 Receptor Agonists (Traditional)

Examples: Liraglutide (Saxenda), Semaglutide (Wegovy) Work by mimicking natural GLP-1
Single target: GLP-1 receptors only

2. Dual Receptor Agonists (Like Tirzepatide)

What researchers call “Twincretin”:

Tirzepatide is a dual agonist for GLP-1 and glucose-dependent
insulinotropic polypeptide
(GIP) receptors
Studies show tirzepatide has greater engagement with GIP
receptors than GLP-1
receptors
Results in 19.5-20.9% weight loss compared to 3.1% with placebo

3. Triple Receptor Agonists (Future Research)

Target GLP-1 + GIP + Glucagon receptors Still in research phase

RESEARCH FINDINGS:

HOW THEY WORK

HOW THEY WORK

1. In the Brain: GLP-1 receptor agonists cross the blood-brain barrier and activate appetite centers

2. In the Stomach: Slow down food emptying

3. In the Pancreas: Help make more insulin when needed

Advanced Research Findings
Tirzepatide’s Unique Properties:

CURRENT RESEARCH DATA

Weight Loss Results
Semaglutide (Wegovy):

Average: 12-15% body weight loss
Up to 83.5% of patients lose ≥5% weight

Tirzepatide (Zepbound):

Average: 16-22% body weight loss, with 89-91% of participants achieving ≥5% weight loss 20.7 to 68.4% lost more than 10% of baseline body weight

Safety Data

Common Side Effects:

Nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain Side effects similar to GLP-1 receptor agonists, mainly gastrointestinal, more common at higher doses

Serious Events:

Cardiovascular events tended to be reduced over up to 2-year period, with hazard ratios <1.0 vs pooled comparators

FUTURE RESEARCH DIRECTIONS
(2025 AND BEYOND)

New Medications Coming

Several new developments expected in 2025:

• Oral GLP-1s: Easier to take pills instead of injections
• Monthly injections: Instead of weekly
• Combination therapies: Multiple hormones in one medicine

New Uses Being Studied

Research expanding beyond diabetes and weight loss:
Heart failure treatment
Sleep apnea (recently approved for tirzepatide)
Kidney disease protection
Potential cognitive benefits

RESEARCH METHODOLOGY NOTES

Clinical Trial Standards
Phase 1: Safety testing in small groups
Phase 2: Effectiveness testing in hundreds of people
Phase 3: Large-scale testing in thousands of people
Post-market: Ongoing safety monitoring
Key Research Programs
STEP trials: Semaglutide weight loss studies
SURPASS trials: Tirzepatide diabetes studies showing unprecedented HbA1c reductions of 1.24-2.58%
SURMOUNT trials: Tirzepatide weight loss studies

IMPORTANT RESEARCH LIMITATIONS

Who Was NOT Included in Studies

Current research has limitations in generalizability to populations excluded from pivotal trials:

Pregnant women
People with certain medical conditions
Some ethnic groups were underrepresented
People with eating disorders

What We Still Don’t Know

Long-term effects beyond 2-3 years
Effects on pregnancy and fertility
Optimal duration of treatment
Best way to stop the medication

Research Summary

Bottom Line:

GLP-1 medications are highly effective for weight loss Dual-action medications (like tirzepatide) work better than
single-action ones
New safety guidelines require using FDA-approved versions only Research continues to expand potential uses

KEY RESEARCH REFERENCES

1. Bessette LG, Anderson TS. Generalizability of clinical trials of novel weight loss medications to the US adult population. JAMA Intern Med. 2024.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus
   semaglutide once weekly in
   patients with type 2 diabetes. N Engl J Med. 2021;385:503-515.
5. Nauck MA, Meier JJ. Tirzepatide, a dual GIP/GLP-1 receptor
   co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control
   and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.

This white paper is intended for educational purposes and should not replace professional medical advice. Healthcare providers should consult current prescribing information and clinical guidelines when making treatment decisions.